Anamorelin

Summary

Anamorelin (CHEMBL2110579) is a phase-3 clinical-stage small molecule targeting GHSR; indicated across 2 conditions including non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (GHSR)
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 546.7 Da · C31H42N6O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110579
Name	Anamorelin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9828911
Molecular formula	C31H42N6O3
Molecular weight	546.7
InChIKey	VQPFSIRUEPQQPP-MXBOTTGLSA-N

SMILES: CC(C)(C(=O)N[C@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@](C3)(CC4=CC=CC=C4)C(=O)N(C)N(C)C)N

IUPAC name: 2-amino-N-[(2R)-1-[(3R)-3-benzyl-3-[dimethylamino(methyl)carbamoyl]piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide

Also known as: Anamorelin, Anamorelina, Anamoreline, RC-1291, ST-1291, ANAMORELIN

Parent form; salt/anhydrous children: CHEMBL2103794

Patent coverage: 109 distinct patent families (273 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GHSR	ghrelin receptor	Agonist	9.24	0.2%	Q92847

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GHSR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Peptide ligand-binding receptors	1	GHSR
G alpha (q) signalling events	1	GHSR

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	1
spermatogenesis	1
learning or memory	1
actin polymerization or depolymerization	1
adult feeding behavior	1
response to hormone	1
hormone-mediated signaling pathway	1
negative regulation of norepinephrine secretion	1
growth hormone secretion	1
response to food	1
negative regulation of appetite	1
positive regulation of appetite	1
response to follicle-stimulating hormone	1
response to estradiol	1
negative regulation of interleukin-1 beta production	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00378131	PHASE2	COMPLETED	Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

169 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ATAZANAVIR	ChEMBL + PubChem	Phase 4 (approved)	GHSR
CINACALCET	ChEMBL + PubChem	Phase 4 (approved)	GHSR
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	GHSR
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	GHSR
LINAGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	GHSR
TEGASEROD	ChEMBL + PubChem	Phase 4 (approved)	GHSR
AMIODARONE	ChEMBL	Phase 4 (approved)	GHSR
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	GHSR
ASENAPINE	ChEMBL	Phase 4 (approved)	GHSR
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	GHSR
ATRACURIUM	ChEMBL	Phase 4 (approved)	GHSR
AZELASTINE	ChEMBL	Phase 4 (approved)	GHSR
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	GHSR
BENFLUOREX	ChEMBL	Phase 4 (approved)	GHSR
BENPERIDOL	ChEMBL	Phase 4 (approved)	GHSR
BEPRIDIL	ChEMBL	Phase 4 (approved)	GHSR
BICALUTAMIDE	ChEMBL	Phase 4 (approved)	GHSR
BOSUTINIB	ChEMBL	Phase 4 (approved)	GHSR
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	GHSR
BROMPERIDOL	ChEMBL	Phase 4 (approved)	GHSR
BUCLIZINE	ChEMBL	Phase 4 (approved)	GHSR
CARVEDILOL	ChEMBL	Phase 4 (approved)	GHSR
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	GHSR
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	GHSR
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	GHSR
CLEMASTINE	ChEMBL	Phase 4 (approved)	GHSR
CLOFAZIMINE	ChEMBL	Phase 4 (approved)	GHSR
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	GHSR
DARIFENACIN	ChEMBL	Phase 4 (approved)	GHSR
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	GHSR
DESERPIDINE	ChEMBL	Phase 4 (approved)	GHSR
DESIPRAMINE	ChEMBL	Phase 4 (approved)	GHSR
DIBUCAINE	ChEMBL	Phase 4 (approved)	GHSR
DICYCLOMINE	ChEMBL	Phase 4 (approved)	GHSR
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	GHSR
DILTIAZEM	ChEMBL	Phase 4 (approved)	GHSR
DOMPERIDONE	ChEMBL	Phase 4 (approved)	GHSR
DULOXETINE	ChEMBL	Phase 4 (approved)	GHSR
EBASTINE	ChEMBL	Phase 4 (approved)	GHSR
FEDRATINIB	ChEMBL	Phase 4 (approved)	GHSR
FENTANYL	ChEMBL	Phase 4 (approved)	GHSR
FLUNITRAZEPAM	ChEMBL	Phase 4 (approved)	GHSR
FLURAZEPAM	ChEMBL	Phase 4 (approved)	GHSR
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	GHSR
HALOPERIDOL	ChEMBL	Phase 4 (approved)	GHSR
IDARUBICIN	ChEMBL	Phase 4 (approved)	GHSR
INDOCYANINE GREEN ACID FORM	ChEMBL	Phase 4 (approved)	GHSR
LANSOPRAZOLE	ChEMBL	Phase 4 (approved)	GHSR
LASOFOXIFENE	ChEMBL	Phase 4 (approved)	GHSR
LIOTHYRONINE	ChEMBL	Phase 4 (approved)	GHSR
LOFEPRAMINE	ChEMBL	Phase 4 (approved)	GHSR
MACIMORELIN	ChEMBL	Phase 4 (approved)	GHSR
MECLIZINE	ChEMBL	Phase 4 (approved)	GHSR
MEFLOQUINE	ChEMBL	Phase 4 (approved)	GHSR
NAFARELIN	ChEMBL	Phase 4 (approved)	GHSR
NEBIVOLOL	ChEMBL	Phase 4 (approved)	GHSR
NERATINIB	ChEMBL	Phase 4 (approved)	GHSR
NIMESULIDE	ChEMBL	Phase 4 (approved)	GHSR
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	GHSR
NOSCAPINE	ChEMBL	Phase 4 (approved)	GHSR